Is United Health Stock Still Undervalued? | UNH Stock Analysis
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 11 Aug 2026, 15:45 UTC
- Recorded by Tahlil Plus
- 11 Aug 2026, 17:47 UTC
AI-generated source summary
The stock UnitedHealth Group (UNH) is currently trading at approximately $403.67. The analysis suggests that the stock has been in a downtrend recently, falling about 10% from its peak of $440. The company's revenue growth has slowed, and management has made decisions to restrict the categories and geography of its offerings, leading to an estimated operating margin of 4.82%. In 2025, the company had to re-evaluate its cost estimates and realized it was underestimating the costs of servicing certain customer segments, leading to a significant drop in operating margins from around 8% to 4%. This trend is expected to continue, with profit margins potentially falling further. The return on invested capital has also seen a similar decline. Historically, the company's return on invested capital increased from 7% in 2017 to 8% by 2025, but it has since declined. This suggests that companies heavily reliant on government contracts may not achieve high profit margins. Despite the recent pullback, the P/E ratio is around 18, which is near the lower end of its historical range over the past few years, suggesting it may be undervalued.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.